Skip to main content
. Author manuscript; available in PMC: 2017 Feb 1.
Published in final edited form as: J Am Acad Dermatol. 2015 Dec 11;74(2):370–371. doi: 10.1016/j.jaad.2015.09.073

Figure 1. Vitiligo repigmentation during treatment with ruxolitinib.

Figure 1

Screening skin examination reveals near-complete depigmentation of the patient’s face at baseline. The first evidence of skin repigmentation appeared after 12 weeks of therapy, which continued until week 20, when ruxolitinib was discontinued. Follow up visit 12 weeks after stopping the treatment shows recurrent depigmentation in the majority of previously repigmented areas. Pigmented areas of the face were outlined using the free-hand selection tool followed by calculation of the % selected area using ImageJ software.